Design: phase 3, double-blind, placebo-controlled, randomised 2:1 across 19 countries
Population: 258 adults with transfusion-dependent alpha or beta thalassaemia, median age 33.5 years, 53% women
Primary outcome: transfusion reduction response over 48 weeks
Effect: 30% vs 13%, adjusted difference 18 percentage points (95% CI 8–27), p=0.0003

Transfusion-dependent thalassaemia is managed by transfusion and iron chelation, and for alpha-thalassaemia there has been no disease-modifying therapy at all. ENERGIZE-T randomised 258 adults with transfusion-dependent alpha or beta thalassaemia across 19 countries, two to one, to 100 mg mitapivat twice daily or placebo for 48 weeks. Mitapivat is an oral allosteric activator of pyruvate kinase, which improves the energy economy of the red cell.

The primary endpoint was a transfusion reduction response: at least a 50% fall in red cell units transfused, and at least two units fewer, over any consecutive 12-week period. It was met by 52 of 171 patients on mitapivat (30%) against 11 of 87 on placebo (13%) — an adjusted difference of 18 percentage points (95% CI 8 to 27, p=0.0003). Adverse events were common in both arms, 90% against 84%, most often headache, upper respiratory infection, early insomnia, diarrhoea and fatigue. Serious adverse events were slightly less frequent on mitapivat (11% against 15%), but discontinuation for adverse events was more frequent (6% against 1%). No deaths occurred.

For Indian practice this matters more than the effect size suggests, because the disease burden here is large and the current pathway — lifelong transfusion plus chelation — consumes an enormous amount of family time and blood bank capacity. Mitapivat is not yet available in India and CDSCO has not acted on it, so the immediate use of this trial is in counselling: a patient asking whether anything oral exists now has a truthful answer, with the honest qualification that most patients in the trial still needed transfusion.

Note that this was an adult trial — nothing here applies to children with thalassaemia
Set expectations carefully: 30% met the transfusion reduction threshold, so most patients continued to require transfusion
Record baseline transfusion requirement in units per 12 weeks, which is how any future response would be judged
Availability in India is not established; do not imply a timeline you cannot support
Continue chelation planning unchanged — nothing in this trial addresses iron burden directly

Why it matters

For alpha-thalassaemia this is the first disease-modifying therapy of any kind, and the first oral one for beta-thalassaemia.

The statistics, in plain English

The 18 percentage point difference has a confidence interval of 8 to 27, which stays well clear of zero — the benefit is real. But read the absolute numbers alongside it: 30% responding means seven in ten patients did not, and the endpoint is a reduction in transfusions rather than freedom from them. A large odds ratio or a small p value says how confident we are that a difference exists, not how much difference a given patient will feel.